Updated:
Debiopharm Group
Debiopharm Group is a Swiss family office and biopharmaceutical company founded in 1979 by Dr. Rolland-Yves Mauvernay, now led by Thierry Mauvernay.
Debiopharm Group
Thierry Mauvernay runs Debiopharm Group, the life sciences arm of the family holding Après-demain SA, founded in 1979 by his father, Dr. Rolland-Yves Mauvernay. The original business model — in-licensing underdeveloped compounds, advancing them into approved medicines, and out-licensing to larger pharma — remains the core of Debiopharm International. The group employs 420 people across its three divisions. The group’s strategy encompasses drug development (oncology, infectious disease), contract manufacturing, and investment in early-stage digital health companies via the Debiopharm Innovation Fund. The portfolio spans artificial-intelligence platforms for clinical trial design, biomarker discovery, patient engagement tools, and digital therapeutics. Confirmed investments include an AI-driven platform for virtual clinical trials, a computational bioplatform for drug outcome prediction, and a precision medicine foundation model for radiology (per the firm's portfolio page, 2026). Debiopharm operates globally, with headquarters in Lausanne, Switzerland. Total deployment and AUM are not publicly disclosed. The firm maintains a single-family-office structure under Après-demain SA, which also manages asset diversification and philanthropic initiatives. No recent operational events (last 24 months) were found in public sources. Debiopharm is structurally distinct because it operates as a fully integrated biopharma company — developing its own drugs and manufacturing them — alongside a venture investment arm. The group does not manage third-party capital; all activities are funded by the Mauvernay family’s pharmaceutical licensing revenue, making it a rare hybrid of operating company and family office.
General information
Firm type
Single Family Office
Year founded
1979
AUM
Undisclosed
Location
Region
Europe
Country
Switzerland
City
Lausanne
Corporate office
Lausanne, Switzerland
Principals
Rolland-Yves Mauvernay
Founder
Thierry Mauvernay
CEO
Sector focus
Frequently asked questions
Who runs investment decisions at Debiopharm Group?
Thierry Mauvernay, the founder's son, serves as CEO and oversees the entire group, including investment decisions for the Debiopharm Innovation Fund. The investment team also includes Marc Cikes, Tom Gibbs, Nicolas Stalder, Vincent Lepreux, and Cedric Odje, per the firm's website.
How does Debiopharm source proprietary deal flow?
The firm sources deals through its drug development and manufacturing operations, which provide visibility into emerging therapeutic technologies and unmet clinical needs. The Debiopharm Innovation Fund specifically targets digital health and smart data startups that can improve clinical trial efficiency or patient outcomes, often leveraging relationships from the core pharma business.
Is Debiopharm structured as a single family office or does it operate more like a venture firm?
Debiopharm is a hybrid: it functions as the life sciences division of the family holding Après-demain SA, making it a single-family office. However, it operates three distinct business lines — drug development, manufacturing, and a venture investment fund — giving it the operational heft of a biopharma company.
Does Debiopharm participate in fund commitments or only direct deals?
The firm focuses exclusively on direct investments through the Debiopharm Innovation Fund, which makes equity investments in early-stage digital health and smart data startups. There is no public evidence of commitments to external venture funds.
What investment stages does Debiopharm typically target?
The Innovation Fund invests in early-stage companies, generally at seed or Series A rounds. Its portfolio features AI-driven platforms, digital therapeutics, and computational bioplatforms — all pre-commercial or early-commercial stage.
Which sectors does Debiopharm explicitly avoid?
The firm explicitly limits its focus to oncology and infectious diseases for drug development, and to digital health and smart data for investments. It does not invest in areas outside life sciences, such as fintech or real estate, based on its website disclosures.
Where does the underlying wealth come from?
The Mauvernay family wealth originates from pharmaceutical licensing revenues generated by Debiopharm's unique business model: in-licensing underdeveloped compounds, conducting clinical development, and out-licensing approved drugs to larger pharmaceutical companies. The group has operated on this model since 1979.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: